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Abstract
Background: Subclinical thyroid dysfunction has been implicated as a risk factor for cognitive decline in old age, but results
are inconsistent. We investigated the association between subclinical thyroid dysfunction and cognitive decline in the
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Methods: Prospective longitudinal study of men and women aged 70–82 years with pre-existing vascular disease or more
than one risk factor to develop this condition (N = 5,154). Participants taking antithyroid medications, thyroid hormone
supplementation and/or amiodarone were excluded. Thyroid function was measured at baseline: subclinical hyper- and
hypothyroidism were defined as thyroid stimulating hormones (TSH) ,0.45 mU/L or .4.50 mU/L respectively, with normal
levels of free thyroxine (FT4). Cognitive performance was tested at baseline and at four subsequent time points during a
mean follow-up of 3 years, using five neuropsychological performance tests.
Results: Subclinical hyperthyroidism and hypothyroidism were found in 65 and 161 participants, respectively. We found no
consistent association of subclinical hyper- or hypothyroidism with altered cognitive performance compared to euthyroid
participants on the individual cognitive tests. Similarly, there was no association with rate of cognitive decline during follow-
up.
Conclusion: We found no consistent evidence that subclinical hyper- or hypothyroidism contribute to cognitive impairment
or decline in old age. Although our data are not in support of treatment of subclinical thyroid dysfunction to prevent
cognitive dysfunction in later life, only large randomized controlled trials can provide definitive evidence.
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Introduction
Subclinical thyroid dysfunction, defined biochemically as a
normal serum level of free thyroxine (FT4) in the presence of a
common finding among the elderly population with a prevalence
of up to 20% [1]. Both subclinical hyper- and hypothyroidism
have been implicated as risk factors for cognitive decline, although
the literature regarding these associations shows inconsistent
results [2–8].
A candidate mechanism to explain a possible association of
subclinical thyroid dysfunction with cognitive decline is cardio-
vascular disease. Cardiovascular disease and its risk factors are
important contributors to cognitive decline in later life [9].
Hypothyroidism is associated with hypertension [10,11], and
higher levels of total cholesterol and low-density lipoprotein (LDL)
cholesterol [12–14], both of which increase the risk of atheroscle-
rosis [15,16]. A recent analysis of 55,287 individual participant
data from 11 prospective cohort studies showed that the
subclinical stage of hypothyroidism is associated with an increased
risk of coronary heart disease events and mortality [17].
Furthermore, it is well established that subclinical hyperthyroidism
is related to an increased risk of atrial fibrillation [15,18,19], which
is an important risk factor for stroke. Hence, both subclinical
hyperthyroidism and hypothyroidism are associated with cardio-
vascular disease and could therefore be important contributors to
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high or low level of thyroid stimulating hormone (TSH), are a
cognitive decline. Inconsistent results of previous studies on the
association of subclinical thyroid dysfunction and cognition could
be explained by small numbers of participants, low burden of
cardiovascular disease and scarcity of longitudinal data.
In the present study, we examined the association of subclinical
thyroid dysfunction and cognitive decline in the PROspective
Study of Pravastatin in the Elderly at Risk (PROSPER), which
consisted of 5,154 participants aged 70–82 years with pre-existing
vascular disease or risk factors thereof.
Methods
Subjects
Participants were part of PROSPER, a multicentre, random-
ized placebo-controlled trial [20]. PROSPER was designed to test
the hypothesis whether treatment with pravastatin reduces the risk
of subsequent major vascular events in a cohort of elderly men and
women with pre-existing vascular disease or at risk of developing
this condition [20]. Briefly, 5,804 participants aged 70 to 82 years
with pre-existing vascular disease or who had more than one risk
factor to develop this condition (defined as hypertension, cigarette
smoking or diabetes mellitus), were randomized to receive
treatment with 40 mg pravastatin per day or matching placebo.
After a 3 to 5-year intervention period, assessments were made on
the influence of this therapy on major vascular events (a
combination of coronary heart disease death, nonfatal myocardial
infarction, and fatal and nonfatal stroke). No effect was found of
pravastatin treatment on cognitive performance during follow-up,
nor was there an effect of pravastatin on TSH during follow-up
[21]. The study was approved by the institutional ethics review
boards of centres of Cork University (Ireland), Glasgow University
(Scotland) and Leiden University Medical Center (the Nether-
lands) and all participants gave written informed consent.
Thyroid function
Because of the distorting effect of antithyroid medications
(Carbimazole, Methimazole and Propylthiouracil), thyroid hor-
mone supplementation (Levothyroxine) and amiodarone on
thyroid function and on cardiovascular disease [22], participants
using any of these medications at baseline were excluded (n= 6,
n = 159 and n= 20 respectively). Blood samples in PROSPER
were collected at baseline. Thyroid function was determined by
state-of-the-art serum immunoassays for TSH (third generation
assays with functional sensitivity of 0.05 mIU/l or less) and for
FT4 in respective laboratory centers (Cork, Ireland; Glasgow,
Scotland; and Leiden, the Netherlands). Inter- and intra-assay
coefficients of variation were less than 5% for both TSH and FT4.
To account for the differences of laboratory assays, we used a
narrow FT4 reference range; values of 12 pmol/L to 18 pmol/L
were considered normal [23]. For TSH, we used a reference range
derived from relevant literature; values of 0.45 mU/L to
4.50 mU/L were considered as normal [1,17]. Subclinical thyroid
dysfunction is defined as a normal serum level of free thyroxine in
the presence of a low or high level of thyroid stimulating hormone.
We defined euthyroidism as a normal serum level of TSH.
To assess the risks associated with persistent subclinical thyroid
dysfunction [24], TSH and FT4 measurements were repeated at 6
months in archived serum samples, which were stored at270uC in
the Glasgow University laboratory. TSH and FT4 were measured
using the same electrochemiluminescence immunodetection
method on a Roche Elecsys 2010 (Burgess Hill; UK). The limit
of detection of TSH was ,0.005 uIU/ml; for FT4 this was
0.3 pmol/L with a reference range of 12 pmol/L to 22 pmol/L
[23].
Cognitive performance
Cognitive performance was tested at baseline, after 9, 18, 30
months and at the end of the study. The time point of this last
measurement varied between 36 and 48 months; therefore, we
performed the analyses with their individually varying time-point,
but report the results for the mean of these time points (at 42
months).
The Mini-Mental-State-Examination (MMSE) was used to
screen for global cognitive dysfunction; participants with a baseline
MMSE-score below 24 points were excluded from PROSPER
[20]. Furthermore, four neuropsychological performance tests
were used to measure executive function and memory [25]. The
Stroop-Colour-Word-Test was used to test selective attention and
reaction time of the participants. The participants were asked to
read a colour name which was displayed in a colour different from
the colour it actually names. The outcome parameter was the total
number of seconds to complete the test; a higher score therefore
indicates worse performance. General cognitive speed was tested
by the Letter-Digit Coding Test. The participants had to match
certain digits with letters according to a provided key. The
outcome variable was the total number of correct entries in 60
seconds, and therefore higher scores represents better perfor-
mance. The Picture-Word Learning Test was used as a verbal
learning test of long-term memory. Fifteen pictures were presented
at the participants, and they were asked to recall as many pictures
as possible in three trials. After 20 minutes they were asked to
repeat the test to measure their delayed recall. The outcome
parameter is the accumulated number of correct recalled pictures,
immediate and after 20 minutes. Higher scores thus indicate better
performance.
Statistical methods
Participants with subclinical hyperthyroidism and subclinical
hypothyroidism were compared to participants with euthyroidism
at baseline by calculating means and percentages of baseline
characteristics. To investigate the cross-sectional association
between subclinical thyroid function and cognitive performance,
we performed linear regression analyses. Adjustments were made
for potential confounders; sex, age, education, country, apo E
genotype, and where appropriate for version of cognitive test. The
effect of thyroid function on cognitive performance during follow-
up was investigated by linear mixed models for repeated
measurements. The models included baseline thyroid function
(subclinical hyperthyroidism, euthyroidism and subclinical hypo-
thyroidism), time (in years) and the interaction term between time
and thyroid function. The dependent variable was the series of
repeated measurement of cognitive performance during follow-up.
The estimated values for thyroid function indicates the cross-
sectional difference in cognition between the two subclinical
groups, as compared to the euthyroid group. The change in
cognition per year during the follow-up period is represented by
the estimated value for annual change over time. The estimated
value for the interaction between time and thyroid function
represents the additional change in cognition per year in
participants with subclinical hyper- or hypothyroidism compared
to euthyroidism. A significant difference in this term would
indicate that cognitive decline over the mean follow-up period of
3.2 years differed between the subclinical thyroid groups and
euthyroidism. Adjustments were made for sex, age, education,
country, study treatment, apo E genotype and where appropriate
for version of cognitive test.
Moreover, to further explore the association between subclinical
thyroid dysfunction and cognitive performance, we performed
several sensitivity analyses in which we 1) used a wider FT4
Results from the PROSPER Study
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reference range, with 10.3 pmol/L to 25.7 pmol/L considered
normal according to relevant literature values [1]; 2) excluded all
participants who started thyroid hormone therapy and/or
antithyroid medications and/or amiodarone during follow-up; 3)
excluded all participants who developed heart failure during
follow-up; and 4) only included participants with persistent
subclinical hyper- or hypothyroidism or persistent euthyroidism,
defined as subclinical hyper- or hypothyroidism or euthyroidism at
both baseline and six months. Additionally, we investigated
whether an association existed between subclinical thyroid status
and cognitive function and decline, which was specific for a lower
or higher global cognitive function (i.e. below or above the median
MMSE score of 27 points) at baseline and which may have been
obscured by analyzing the cohort as a whole. We did similar
analyses for participants with and without pre-existing vascular
disease or risk factors (current smoking, history of diabetes and/or
history of hypertension) thereof; with an age of leaving school
below or above the median value of 14 years; and with a very low
(,0.1 mU/L) or very high TSH-value (.10 mU/L). P-values less
than 0.05 were considered statistically significant. All analyses
were performed with SPSS (version 17.0, PASW Statistics Inc,
Chicago, III).
Results
Figure 1 shows the flowchart of study participants. From all
participants of PROSPER (n= 5,804), a number of 650 were
excluded, resulting in 5,154 participants for the present analyses.
We categorized these participants into three different thyroid
status groups. A total of 4,928 participants were euthyroid.
Subclinical hyperthyroidism was found in 65 of the participants.
Subclinical hypothyroidism was found in 161 of the participants.
Treatment with pravastatin was evenly distributed among the
three groups (data not shown).
Table 1 shows the baseline characteristics of the study
participants per thyroid status group. In euthyroid participants,
gender was almost evenly distributed (48.6% females), while in
both subclinical groups females were overrepresented (73.8% and
64.0%, both p-values ,0.01). There was no significant age
difference between the three groups. All three groups had a similar
score on Barthel test and on Instrumental Activities of Daily Living
scale.
In line with expectation, participants with subclinical hyperthy-
roidism had a lower body mass index compared to the euthyroid
group (mean; 25.69 vs. 26.81, p = 0.03). There was no significant
difference in systolic and diastolic blood pressure at baseline
between the groups. Subclinical hypothyroidism was associated
with a higher prevalence of hypertension (69.6% vs. 61.0%,
p= 0.03). There was no significant difference in prevalence of
smokers, history of diabetes, vascular disease and/or TIA/stroke
between the groups. All three groups had a similar lipid profile.
The association of thyroid status and cognitive performance at
baseline is presented in table 2. There was no significant difference
in Mini-Mental State Examination, Stroop test, Letter-Digit
Coding test and delayed Picture-Word Learning test at baseline
between participants with subclinical hyperthyroidism or hypo-
thyroidism when compared to participants with euthyroidism (all
p-values.0.05). Participants with subclinical hypothyroidism had
a higher score on immediate Picture-Word Learning test, although
not statistically significant (mean; 9.45 vs. 9.72, p = 0.06).
The longitudinal association between thyroid status and
cognitive decline is shown in table 3. As expected, there was a
significant annual decline among the total study population in
each cognitive performance test (all p-values,0.001), with an
exception of the MMSE test (p-value = 0.31). The Mini-Mental
Figure 1. Flowchart of study participants. Abbreviations: TSH, Thyroid Stimulating Hormone; FT4, free thyroxine.
doi:10.1371/journal.pone.0059199.g001
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State Examination showed an additional increase in participants
with subclinical hypothyroidism compared to participants with
euthyroidism (estimate; 0.08, p = 0.03). There was no significant
additional change per year during follow-up in Stroop test, Letter-
Digit Coding test and immediate and delayed Picture-Word
Learning test scores in participants with subclinical hyper- and
hypothyroidism compared to participants with euthyroidism.
Furthermore, sensitivity analyses in which we 1) used a wider
FT4 reference range with normal FT4 values between 10.3 pmol/
L and 25.7 pmol/L; 2) excluded all participants who started
Table 1. Baseline characteristics of study participants grouped by thyroid status.
Thyroid status p-value for difference
Subclinical
hyperthyroidism
N=65
Euthyroidism
N=4,928
Subclinical
hypothyroidism
N=161
Subclinical
hyperthyroidism vs.
euthyroidism
Subclinical
hypothyroidism vs.
euthyroidism
Demographics
Female, n (%) 48 (73.8%) 2,394 (48.6%) 103 (64.0%) ,0.001 ,0.001
Age (years), mean (se) 75.33 (0.38) 75.28 (0.05) 75.63 (0.25) 0.90 0.20
Education (years), mean (se) 15.29 (0.27) 15.14 (0.03) 15.17 (0.17) 0.56 0.89
Barthel score, mean (se)* 19.63 (0.09) 19.78 (0.01) 19.86 (0.06) 0.08 0.18
IADL score, mean (se) * 13.59 (0.12) 13.65 (0.01) 13.64 (0.08) 0.62 0.95
Biometrics, mean (se)*
Weight (kg) 71.73 (1.51) 73.47 (0.17) 74.76 (0.96) 0.25 0.19
Height (cm) 166.60 (0.83) 165.43 (0.10) 166.58 (0.52) 0.15 0.03
BMI (kg/m2) 25.69 (0.51) 26.81 (0.06) 26.88 (0.33) 0.03 0.83
SBP (mmHg) 153.79 (2.70) 154.60 (0.31) 156.77 (0.72) 0.77 0.21
DBP (mmHg) 82.60 (1.42) 83.86 (0.16) 84.50 (0.90) 0.38 0.49
Risk factors, n (%)
Current smoker 12 (18.5%) 1,367 (27.7%) 36 (22.4%) 0.10 0.13
History of diabetes 10 (15.4%) 525 (10.7%) 23 (14.3%) 0.22 0.14
History of hypertension 38 (58.5%) 3,008 (61.0%) 112 (69.6%) 0.67 0.03
History of vascular disease 25 (40.0%) 2177 (44.2%) 67 (41.6%) 0.50 0.52
History of TIA/stroke 6 (9.2%) 552 (11.2%) 20 (12.4%) 0.62 0.63
Lipid profile, mean (se)*
HDL cholesterol (mmol/L) 1.24 (0.04) 1.28 (0.01) 1.27 (0.03) 0.32 0.62
LDL cholesterol (mmol/L) 3.82 (0.10) 3.78 (0.01) 3.86 (0.06) 0.69 0.20
Total cholesterol (mmol/L) 5.70 (0.11) 5.67 (0.01) 5.77 (0.07) 0.80 0.14
Triglycerids (mmol/L) 1.57 (0.09) 1.54 (0.01) 1.56 (0.05) 0.74 0.78
Abbreviations: n, number; se, standard error; IADL, Instrumental Activities of Daily Living; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; TIA, transient ischemic attack; HDL, high density cholesterol lipoprotein; LDL, low density cholesterol lipoprotein.
* = adjusted for sex and age at baseline, assessed by linear regression.
doi:10.1371/journal.pone.0059199.t001
Table 2. Association of subclinical thyroid status and various cognitive performance tests at baseline.
Thyroid status p-value for difference
Cognitive test
Subclinical
hyperthyroidism
N=65
Euthyroidism
N=4,928
Subclinical
hypothyroidism
N=161
Subclinical
hyperthyroidism vs.
euthyroidism
Subclinical
hypothyroidism vs.
euthyroidism
MMSE, score 28.04 (0.19) 28.04 (0.03) 27.87 (0.12) 0.97 0.15
Stroop, seconds 65.61 (3.07) 65.34 (0.46) 65.90 (2.02) 0.93 0.78
LDCT, digits coded 24.31 (0.86) 23.63 (0.13) 23.51 (0.54) 0.42 0.79
PLTi, pictures remembered 9.29 (0.23) 9.45 (0.03) 9.72 (0.14) 0.50 0.06
PLTd, pictures remembered 10.31 (0.32) 10.30 (0.05) 10.65 (0.20) 0.97 0.09
Abbreviations: MMSE, Mini-Mental State Examination; LDCT, Letter-Digit Coding Test; PLTi, Picture-Word Learning Test immediate; PLTd, Picture-Word Learning Test
delayed. Cognitive tests were presented in mean (standard error). Associations were assessed by linear regression analyses, adjusted for sex, age, education, country,
apo E genotype and test version where appropriate.
doi:10.1371/journal.pone.0059199.t002
Results from the PROSPER Study
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thyroid hormone therapy and/or antithyroid medications and/or
amiodarone during follow-up (n = 138); 3) excluded all participants
who developed heart failure during follow-up (n= 200); and 4)
only included participants with persistent subclinical hyperthy-
roidism (n = 41) or hypothyroidism (n= 90) or persistent euthy-
roidism (n= 4447), did not show any differences of our results
(data not shown). Additional analyses in subgroups (participants
with a MMSE-score below or above the median MMSE score,
with or without pre-existing vascular disease, with or without risk
factors for vascular disease (smoking, hypertension and/or
diabetes), with an age left school below or above the median
value and participants with a very low or very high TSH-value)
also did not change our findings (data not shown).
Thyroid status was not associated with an altered risk of stroke
during follow-up (data not shown). However, the number of
strokes during follow-up was small (n = 242) and therefore power
was limited. Excluding these participants from the analyses did not
materially change our results (data not shown).
Discussion
In this large prospective cohort study, we found no association
between subclinical thyroid dysfunction and cognitive perfor-
mance at baseline and during follow-up among 5,154 participants
aged 70–82 years old with vascular disease or at risk thereof. This
is the largest follow-up study with repeated measurement of
cognitive performance and repeated TSH/FT4 measurements in
an elderly population, which adds further knowledge to previous
cross-sectional studies and shorter longitudinal studies [2–8,26,27].
Clinical guidelines for various diseases, including dementia,
recommend screening for subclinical thyroid disease in old age
[28–30]. Although the condition has been implicated as a risk
factor for cognitive decline, the clinical relevance of this finding
still remains controversial [31–33]. Literature about the associa-
tion between subclinical thyroid dysfunction and cognitive
performance has shown conflicting results [2–8,26,27]. A few
cross-sectional studies showed that subclinical hyperthyroidism
was associated with lower cognitive performance, although the
number of participants with subclinical hyperthyroidism was
relatively small [2,3]. In one large cross-sectional study of 5,865
participants with a mean age of 73.6 years, no association was
found between subclinical thyroid dysfunction and anxiety,
depression or cognitive impairment [7]. One longitudinal study
with 1,843 nondemented participants with a mean age of 68.8
years demonstrated an association between subclinical hyperthy-
roidism and an increased risk of dementia and Alzheimer’s disease
[6]. Finally, the scarce randomized controlled trials concerning
this association included few participants (n,100) and had
relatively short follow-up (12 months) [26,27]. Only one trial
showed an improvement of thyroid hormone replacement on
cognitive performance, although mean age in the study was low
(62 years); and therefore not representative for the elderly [26].
There might be several explanations why we found no
association of subclinical thyroid dysfunction with cognitive
performance or decline. In the first place, it is well-established
that participants with subclinical hypothyroidism may revert to
euthyroidism within a short time [24]. The temporary change of
TSH concentration in non-thyroidal illness could be of too short
duration to cause permanent brain lesions. However, sensitivity
analyses with only inclusion of participants with persistent
subclinical hyper- or hypothyroidism or persistent euthyroidism
yielded no differences of our results. Nevertheless, this could be
explained by lack of power. Second, high levels of TSH could
serve as a possible protective mechanism, thereby preventing
cognitive decline in the elderly. This is supported by a recent study
that found positive effects and better survival in participants with
higher levels of TSH [4]. The speculated beneficial effect of
subclinical hypothyroidism on cognition could therefore conceal
the negative effects of vascular disease or its risk factors on
cognitive performance in our study.
The finding that subclinical hypothyroidism is associated with
increased risk of coronary heart disease [10,16,17,23] could be a
prominent candidate mechanism of how the condition could lead
to cognitive decline. Since PROSPER only consist of participants
suffering from coronary heart disease or at risk thereof, our study
population would be highly suitable to detect such an association.
However, most of the associations found in subclinical hypothy-
roidism concerned in particular participants with a TSH
concentration of 10 mU/L or above [17]; and our data only
had a small number of participants with this TSH concentration
(n= 21). Furthermore, although we know that vascular risk factors
have a detrimental impact on middle age; their negative
association with vascular disease seems to attenuate in old age.
For instance, high total cholesterol concentration is not a risk
factor for vascular disease in elderly people, but instead, is
associated with a lower mortality and increased longevity [34,35],
also in the population under study [35]. Additionally, high blood
pressure values even associate with better survival in the elderly
Table 3. Association of thyroid status with cognitive performance during follow-up.
Annual change in cognitive test
score Additional change
Cognitive test All participants
Subclinical hyperthyroidism vs.
euthyroidism
Subclinical hypothyroidism vs.
euthyroidism
Est (se) p-value Est (se) p-value Est (se) p-value
MMSE, score 0.01 (0.01) 0.31 20.03 (0.06) 0.61 0.08 (0.04) 0.03
Stroop, seconds 0.68 (0.07) ,0.001 20.48 (0.64) 0.45 0.70 (0.41) 0.09
LDCT, digits coded 20.35 (0.02) ,0.001 20.10 (0.14) 0.45 20.02 (0.09) 0.85
PLTi, pictures remembered 20.02 (0.01) ,0.001 20.07 (0.06) 0.23 0.03 (0.04) 0.46
PLTd, pictures remembered 20.07 (0.01) ,0.001 20.13 (0.08) 0.13 0.00 (0.05) 0.94
Abbreviations: Est, estimates; se, standard error; MMSE, Mini-Mental State Examination; LDCT, Letter-Digit Coding Test; PLTi, Picture-Word Learning Test immediate;
PLTd, Picture-Word Learning Test delayed. Estimates represent the additional change in various cognitive performance tests per year in different subclinical thyroid
status. Adjusted for sex, age, education, country, treatment, apo E genotype and test version where appropriate.
doi:10.1371/journal.pone.0059199.t003
Results from the PROSPER Study
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[36]. Taking all data together, we favor the interpretation that
there is insufficient evidence of a relationship of subclinical thyroid
dysfunction and cognitive decline in old age.
A strength of our study is the large sample size of 5,154 elderly
participants, with an overall high prevalence of subclinical thyroid
dysfunction. As we assessed change in cognitive performance with
several sensitive cognitive tests [25], it is unlikely that we missed a
clinically significant cognitive decline in this population. During
the mean follow-up period of three years the cognitive test battery
was repeated up to five times in each individual, resulting in a
detailed and reliable measurement of cognitive function and
decline. Furthermore, the preexistence of vascular disease or at
least one risk factor to develop this condition made our study
population highly appropriate to detect a possible association.
Among limitations, PROSPER only consisted of participants
with a MMSE score of 24 points or higher, which may limit the
generalizability of our results to elderly with cognitive dysfunction.
Furthermore, it is likely that, as a result of selection on MMSE
score, the power to detect an annual decline in cognition might be
limited in our study. However, we did find a significant annual
decline in cognitive function for Stroop test, Letter-Digit Coding
test and immediate and delayed Picture-Word Learning tests in
our study population. Additionally, the cognitive test battery we
used has been proven to detect differences in annual cognitive
decline among different groups in earlier studies [37,38].
Nevertheless, our study showed no consistent difference in
cognitive decline between participants with subclinical hyperthy-
roidism, euthyroidism and subclinical hypothyroidism. Finally, we
may have excluded participants who had clinically significant
cognitive deficits due to thyroid dysfunction at baseline. However,
this limitation has likely resulted in a more homogeneous study
population.
In conclusion, we found no association between subclinical
thyroid dysfunction and cognitive performance at baseline and
during three years of follow-up in a large group of elderly people
with vascular disease or risk factors. Although our data are not in
support of treatment of subclinical thyroid dysfunction to prevent
cognitive dysfunction in later life, only large randomized
controlled trials can provide definitive evidence.
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